Compare NSYS & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSYS | NNVC |
|---|---|---|
| Founded | 1981 | 2005 |
| Country | United States | United States |
| Employees | 713 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.1M | 37.9M |
| IPO Year | 1996 | 2008 |
| Metric | NSYS | NNVC |
|---|---|---|
| Price | $14.50 | $1.52 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 20.9K | ★ 375.6K |
| Earning Date | 05-13-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.85 | 10.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $14,371,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.01 | N/A |
| 52 Week Low | $6.50 | $0.85 |
| 52 Week High | $18.01 | $2.23 |
| Indicator | NSYS | NNVC |
|---|---|---|
| Relative Strength Index (RSI) | 47.34 | 48.51 |
| Support Level | $11.94 | $1.18 |
| Resistance Level | $15.11 | $1.63 |
| Average True Range (ATR) | 0.98 | 0.15 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 57.41 | 17.22 |
Nortech Systems Inc is a United States-based electronic manufacturing services company. It offers value-added engineering, technical, and manufacturing services and support, including project management, design, testing, prototyping, manufacturing, supply chain management, and post-market services. The company's manufacturing and engineering services include complete medical devices, printed circuit board assemblies, wire and cable assemblies, and complex higher-level electro-mechanical assemblies. It operates in the Medical, Aerospace, Defense, and Industrial markets, with key revenue coming from medical-related markets.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.